Dietz Matthieu, Dunet Vincent, Mantziari Styliani, Pomoni Anastasia, Dias Correia Ricardo, Testart Dardel Nathalie, Boughdad Sarah, Nicod Lalonde Marie, Treglia Giorgio, Schafer Markus, Schaefer Niklaus, Prior John O
Nuclear Medicine and Molecular Imaging Department, Lausanne University Hospital, Rue du Bugnon 46, 1011, Lausanne, Switzerland.
INSERM U1060, CarMeN Laboratory, University of Lyon, Lyon, France.
Eur J Hybrid Imaging. 2023 Feb 1;7(1):3. doi: 10.1186/s41824-023-00162-9.
The primary aims of this study were to compare in patients with esophageal or esophagogastric junction cancers the potential of Ga-NODAGA-RGD PET/CT with that of F-FDG PET/CT regarding tumoral uptake and distribution, as well as histopathologic examination.
Ten Ga-NODAGA-RGD and ten F-FDG PET/CT were performed in nine prospectively included participants (1 woman; aged 58 ± 8.4 y, range 40-69 y). Maximum SUV (SUV) and metabolic tumor volumes (MTV) were calculated. The Mann-Whitney U test and Spearman correlation analysis (ρ) were used.
Ga-NODAGA-RGD PET/CT detected positive uptake in 10 primary sites (8 for primary tumors and 2 for local relapse suspicion), 6 lymph nodes and 3 skeletal sites. F-FDG PET/CT detected positive uptake in the same sites but also in 16 additional lymph nodes and 1 adrenal gland. On a lesion-based analysis, SUV of F-FDG was significantly higher than those of Ga-NODAGA-RGD (4.9 [3.7-11.3] vs. 3.2 [2.6-4.2] g/mL, p = 0.014). Only one participant showed a higher SUV in an osseous metastasis with Ga-NODAGA-RGD as compared to F-FDG (6.6 vs. 3.9 g/mL). Correlation analysis showed positive correlation between F-FDG and Ga-NODAGA-RGD PET parameters (ρ = 0.56, p = 0.012 for SUV, ρ = 0.78, p < 0.001 for lesion-to-background ratios and ρ = 0.58, p = 0.024 for MTV). We observed that F-FDG uptake was homogenous inside all the confirmed primary sites (n = 9). In contrast, Ga-NODAGA-RGD PET showed more heterogenous uptake in 6 out of the 9 confirmed primary sites (67%), seen mostly in the periphery of the tumor in 5 out of the 9 confirmed primary sites (56%), and showed slight extensions into perilesional structures in 5 out of the 9 confirmed primary sites (56%).
In conclusion, Ga-NODAGA-RGD has lower potential in the detection of esophageal or esophagogastric junction malignancies compared to F-FDG. However, the results suggest that PET imaging of integrin αβ expression may provide complementary information and could aid in tumor diversity and delineation.
Trial registration: NCT02666547. Registered January 28, 2016-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT02666547 .
本研究的主要目的是比较食管或食管胃交界癌患者中,镓标记的NODAGA-RGD PET/CT与氟代脱氧葡萄糖(F-FDG)PET/CT在肿瘤摄取、分布以及组织病理学检查方面的潜力。
对9名前瞻性纳入的参与者(1名女性;年龄58±8.4岁,范围40-69岁)进行了10次镓标记的NODAGA-RGD和10次F-FDG PET/CT检查。计算了最大标准化摄取值(SUV)和代谢肿瘤体积(MTV)。采用曼-惠特尼U检验和斯皮尔曼相关性分析(ρ)。
镓标记的NODAGA-RGD PET/CT在10个原发部位检测到阳性摄取(8个为原发性肿瘤,2个为怀疑局部复发)、6个淋巴结和3个骨骼部位。F-FDG PET/CT在相同部位检测到阳性摄取,但还在另外16个淋巴结和1个肾上腺中检测到。基于病灶的分析显示,F-FDG的SUV显著高于镓标记的NODAGA-RGD(4.9[3.7-11.3] vs. 3.2[2.6-4.2]g/mL,p = 0.014)。只有1名参与者在骨转移中镓标记的NODAGA-RGD的SUV高于F-FDG(6.6 vs. 3.9 g/mL)。相关性分析显示,F-FDG与镓标记的NODAGA-RGD PET参数之间呈正相关(SUV的ρ = 0.56,p = 0.012;病灶与背景比值的ρ = 0.78,p < 0.001;MTV的ρ = 0.58,p = 0.024)。我们观察到,F-FDG在所有确诊的原发部位(n = 9)内摄取均匀。相比之下,镓标记的NODAGA-RGD PET在9个确诊的原发部位中的6个(67%)显示摄取更不均匀,其中9个确诊的原发部位中的5个(56%)主要见于肿瘤周边,9个确诊的原发部位中的5个(56%)显示向病灶周围结构有轻微延伸。
总之,与F-FDG相比,镓标记的NODAGA-RGD在检测食管或食管胃交界恶性肿瘤方面潜力较低。然而,结果表明整合素αβ表达的PET成像可能提供补充信息,并有助于肿瘤的鉴别和勾勒。
试验注册:NCT02666547。2016年1月28日注册——回顾性注册,https://clinicaltrials.gov/ct2/show/NCT02666547 。